Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-12-23
2000-04-04
Celsa, Bennett
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 18, 530329, 530331, 424439, 426656, 435 711, C07K 508, C07K 706, A61K 3806, A61K 3808
Patent
active
060461683
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a novel peptide inhibiting elevations of triglyceride levels in blood; an agent for inhibiting elevations of triglyceride levels in blood comprising the peptide as an active component; a food for specified health use (the so-called physiologically functional food) endowed with a function of inhibiting elevations of triglyceride levels in blood; and a feed endowed with a function of inhibiting elevations of triglyceride levels in blood.
By administering the agent of the invention inhibiting elevations of triglyceride levels in blood to thereby clean fatty blood, it becomes possible to prevent or treat obesity and hyperlipemia in humans and animals as well as cardiovascular diseases such as hypertension and arteriosclerosis associated therewith. Furthermore, it becomes possible to improve the meat quality of livestock and hatchery fish.
BACKGROUND ART
Excessive intake of fat and sugar is known to cause obesity, hyperlipemia and the like. Elevations of triglyceride (hereinafter, sometimes referred to as "TG") levels in blood in hyperlipemia are said to become a cause which brings disorders such as hypertension and arteriosclerosis. Then, a number of attempts to inhibit elevations of TG levels in blood have been made to improve obesity and hyperlipemia.
At present, in order to inhibit elevations of TG levels in blood, dietary restriction, intake of dietary foods (such as fibers) and administration of various pharmaceuticals are carried out. As such pharmaceuticals, dextran sulfate which enhances lipoprotein lipase activity in blood, nicomol which inhibits lipid absorption, clofibrate and pravastatin which are lipid metabolism improving agents, and the like are used.
However, dietary restriction gives pain to those who practice it and side effects caused by the administration of the above pharmaceuticals are also apprehended. Thus, development of an agent for inhibiting elevations of blood TG levels is desired which has a stronger effect of inhibiting elevations of blood TG levels and in which there is no apprehension about causing side effects.
On the other hand, at present, concentrated feeds are given to livestock and hatchery fish for promoting their growth. As a result, abnormalities in fat metabolism occur also in such livestock and fish, and TG levels in their blood tend to elevate. Due to these elevations of TG levels in blood, fat contents in livestock and hatchery fish become excessive. Thus, eating such livestock or fish leads to excessive fat intake. Furthermore, such livestock and fish have gradually failed to meet consumers' liking in taste. In addition, the increase in fat contents described above is a serious issue relating to a problem of waste of feeds and also relating to a problem of disposal of the fat attached to slaughtered bodies. Thus, inhibition of elevations of TG levels in blood is an urgent need, in particular, in the stockbreeding industry and the fisheries industry in Japan.
Recently, a patent application has been filed for an oligopeptide-containing material developed by some researchers including one of the present inventors (International Publication No. WO89/06970), and a technology similar to this is disclosed in Japanese Unexamined Patent Publication No. 2-154693.
Also, it has been made clear that specific oligopeptides have lipid metabolism improving effects including inhibition of elevations in blood TG levels Kyoichi Kagawa, Food Chemical Monthly, Vol. 6, No. 2, p. 80-84 (1990); Chizuko Fukuhama et al., FOLIA PHARMACOLOGICA JAPONICA, Vol. 97, p.38 (1991).
DISCLOSURE OF THE INVENTION
The oligopeptide-containing materials disclosed in the above patent publication, etc. are mixtures of proteolysates and, thus, amino acid sequences for their truly active components (i.e., peptides as their active components) have not yet been elucidated.
This suggests that the above peptide-containing materials are low in purity as pharmaceuticals. Further, when such a material is combined in a food, it is difficult to quantitatively det
REFERENCES:
patent: 5723443 (1998-03-01), Kagawa et al.
patent: 5756467 (1998-05-01), Kagawa et al.
Karelin et al., Biochem. Biophys. Res. Commun. vol. 202 No. 1 (Jul. 15, 1994) pp. 410-415.
WPIDS Abstract No. 91-084519 of JP 03031298, Feb. 1991.
English Absrtact of JP 3-167199, Jul. 1991.
Fukuhama Chizuko
Honda Kazuhisa
Kagawa Kyoichi
Matsutaka Hisako
Nakamura Toyoo
Celsa Bennett
Hankyu-Kyoei Bussan Co. Ltd.
Itoham Foods Inc.
LandOfFree
Peptide inhibits blood triglyceride level does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide inhibits blood triglyceride level, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide inhibits blood triglyceride level will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-365085